Nasdaq
$2.42▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $245.8MShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.9After-hours26.10.10 06:223/AOwnership#●●●
AC Immune SA
Thomas Graney of AC Immune SA has filed a Power of Attorney to authorize Matthias Maurer, Christopher Roberts, and Tim Kay to handle SEC filings on his behalf. This document grants these individuals the authority to execute and submit required forms, including Forms 3, 4, 5, and 144, through the SEC's EDGAR system.…more
$2.42+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9Pre-market26.10.09 21:083Ownership
AC Immune SA
Executive Thomas Graney has filed a Form 3 report disclosing his initial beneficial ownership of AC Immune SA securities as of October 2, 2026. This filing serves as an official notification of the executive's equity position.…more
$2.42+0.00%vs prev closeView filingShare - 10.2Pre-market26.10.02 21:026-KKey event
AC Immune SA
AC Immune held an Extraordinary General Meeting on October 2, 2026, where shareholders approved the election of Tom Graney as a member of the Board of Directors. His term will continue until the conclusion of the 2027 Annual General Meeting.…more
$2.42+0.00%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Regular26.09.24 00:08#●●●#●●●#●●●
AC Immune Reports 100% Antibody Response in Parkinson’s Drug Phase 2 Trial…more
AC Immune confirmed that its Parkinson’s disease candidate ACI-7104 achieved a 100% antibody response in the first part of its Phase 2 trial. The company plans to consult with regulators to finalize the design for the next phase of clinical development.…more
$2.42+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Pre-market26.09.23 20:05
●●●●●●●● ●●●●● ●●●●●●
AC Immune announced that its ACI-7104 Parkinson's disease candidate met all primary safety and immunogenicity endpoints in the first part of its Phase 2 trial. While the results support moving toward the next phase of the study, clinical efficacy remains to be confirmed in future evaluations.…more
$2.42+0.00%vs prev closeShareBenzinga - 8.20Regular26.08.21 01:32
●●●●●●●● ●●●●● ●●●●●●
AC Immune confirmed the safety and brain penetration of its NLRP3 inhibitor ACI-19764 in Phase 1 clinical trials. The company is now expanding into Phase 1b testing with patients at risk for cardiovascular disease, expecting initial results by year-end.…more
$2.42+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report